

Star Health

BSE SENSEX 77,100 S&P CNX 24,056



Bloomberg	STARHEAL IN
Equity Shares (m)	588
M.Cap.(INRb)/(USD\$)	338.3 / 3.6
52-Week Range (INR)	597 / 413
1, 6, 12 Rel. Per (%)	9/35/38
12M Avg Val (INR M)	431

Financials Snapshot (INR b)

Y/E March	2026	2027E	2028E
NEP	166.0	193.4	222.1
U/W Profit	-4.1	-2.9	-2.0
PBT	7.5	12.1	15.8
PAT	5.6	9.1	11.8

Ratios (%)

Claims	68.5	68.0	68.0
Commission	15.1	15.0	15.0
Expense	16.8	16.3	15.8
Combined	100.5	99.3	98.8
RoE	7.6	11.3	13.0
EPS (INR)	9.5	15.4	20.1
EPS growth	-13.9	63.2	30.2

Valuations


P/E (x)	61.0	37.4	28.7
P/BV (x)	4.5	4.0	3.5

Shareholding Pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	58.0	58.0	57.7
DII	20.3	21.0	15.4
FII	15.1	14.1	18.7
Others	6.7	7.0	8.2

FII includes depository receipts

Stock's Performance (one-year)



CMP: INR575

TP: INR700 (+22%)

Buy

Creating a disciplined leadership story!

- Retail health insurance – the fastest-growing non-life insurance segment (FY20-25 CAGR of 18%), has witnessed stellar growth of ~30% in 2HFY26, supported by rising healthcare inflation, improving awareness, increasing middle-class penetration and GST exemption. However, penetration at <5% of Indian population leaves a long runway for steady high-teen growth.
- Against this backdrop, Star Health and Allied Insurance (STARHEAL) – the largest retail health player with 30%+ market share since FY21 – has seen its retail health GWP growth trajectory improve from 17% CAGR over FY21-26 to 20%+ since Oct'25 to date, while the number of lives covered has seen a 12% CAGR over FY20-25 (vs. 7% for industry).
- After witnessing unfavorable claims experience in FY25 (retail loss ratio of 69.2% vs. 65.8% in FY24), STARHEAL's underwriting performance has recovered on the back of strong fresh business growth (+37% YoY in FY26) and calibrated repricing actions with retail loss ratio at 68.2% in FY26. Going forward, the annual repricing on 80% of the portfolio should reflect in further improvement of the loss ratio, along with continued momentum in fresh business.
- The company has simultaneously recalibrated its group health strategy toward profitability-focused growth by reducing exposure to loss-making corporate accounts and increasing focus on SME/MSME and benefit-led businesses. While the contribution of group health has declined to <5%, this has led to an improvement in the group loss ratio from 90.8% in FY25 to 79.1% in FY26.
- STARHEAL's competitive moat is anchored to its agency-led distribution architecture (830,000 agents in FY26) with continuous improvement in agent productivity (INR430,000 in FY26). Along with increasing productivity of agents, the rising contribution of digital channel should support the acquisition of younger and profitable customers.
- Regulatory developments around EoM, commissions, solvency and IFRS reporting could materially reshape industry economics over the medium term. However, STARHEAL's dominant proprietary distribution mix, lower dependence on institutional channels and improving operating leverage potentially position the company relatively better within the evolving regulatory framework.
- We estimate a CAGR of 16%/32% in IFRS insurance revenue/PAT during FY26-28, with the CISR improving to 98.3% in FY28E. We maintain BUY rating on the stock with a TP of INR700 (valuing the company at 26x FY28E IFRS PAT).

Retail health opportunity continues to deepen

- India's retail health GWP saw a strong CAGR of 18% over FY20-25, backed by improving awareness, rising healthcare inflation and high proportion of out-of-pocket expenditure in India. In comparison, the number of lives covered has increased at a 7% CAGR for the similar period to ~60.1m lives. Compared to Indian population of ~1.4b, the penetration is less than 5%, leaving a long runway for sustained growth in retail health.

Research Analyst: Prayesh Jain (Prayesh.Jain@MotilalOswal.com) | Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com)


Research Analyst: Kartikeya Mohata (Kartikeya.Mohata@MotilalOswal.com) | Muskan Chopra (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.


- GWP growth declined to ~8% in 1HFY26 due to the implementation of 1/n accounting in Oct'24. With the GST exemption announced from 22nd Sep'24, 2HFY26 witnessed a stellar growth of ~30%, which has continued in Apr'26/ May'26 (+31%/+30% YoY) as well. Better affordability and deepening insurance penetration are fueling growth backed by a rising middle class.
- While the growth is also coming from a low base (1/n impact), STARHEAL, the largest retail health player, expects that the structurally under penetrated retail health market should grow at a sustainable trajectory of 16-18%, driven by a mix of both value and volume growth.
- The regulator's increasing focus on reducing expenses and distributor payouts reflects a broader intent to improve insurance penetration. While traditional agency channel should not face significant disruption, growth coming from institutional distributors and high-payout channels may see some near-term impact.
- At the same time, the group health market is gradually moving toward better pricing discipline and profitability-focused growth, resulting in group health GWP growth moderating from 19% (FY20-25 CAGR) to mid-teens.

Exhibit 1: Retail health GWP maintaining strong growth momentum...




Source: MOFSL, GI Council

Exhibit 2: ...but number of lives covered reflect under-penetration



Source: MOFSL, IRDAI

Exhibit 3: Group health growth trajectory moderated




Source: MOFSL, IRDAI

STARHEAL's fresh business growth trajectory improves


- STARHEAL continues to consolidate its position as the leading retail health insurer in the country, with a retail health GWP market share of 31.3% (maintaining 30%+ market share since FY21). The retail health GWP has grown at a CAGR of ~17% during FY21-26, with growth exceeding 20% since Oct'25 (GST exemption boost).
- No. of lives covered has grown at a CAGR of 12% over FY20-25 for STARHEAL compared to 7% for the industry, with the insurer maintaining 33%+ market share since FY22.
- Fresh retail business growth accelerated materially during FY26, with fresh GWP reaching ~INR46b, representing ~37% growth YoY (25% YoY in FY25). The strong growth has been driven majorly by value as the number of retail health policies grew 8% YoY.
- Quality of the fresh business cohort is superior vs. the historical portfolio with the average sum insured in fresh business at ~INR1.2m compared to the overall retail portfolio average of ~INR1m, supporting better ticket sizes and stronger premium growth.
- The renewal ratio has improved 200bp to 99% in FY26, reflecting customers opting for higher sum insured as well as riders. In addition, the new cohorts are significantly younger relative to the back book, reflecting better profitability.
- ~20% of fresh retail business now emerges through digital channels with fresh GWP from digital channels doubling from FY24 to FY26. Digitally acquired cohorts being materially younger than offline cohorts could have meaningful implications for long-term claims behavior and persistency.
- The insurer also continues to focus heavily on the new-to-insurance segment (~93-94% of new business), while portability-led business showcases the deepening penetration of the insurer.
- Increasing contribution from long-term policies at 10%+ will help the insurer in reducing early-stage leakage, enhancing persistency, improving visibility of renewal streams and providing upfront float benefits.
- While STARHEAL is pursuing selective growth in certain geographies and customer cohorts, the strong growth trajectory of fresh business reflects a clear pivot towards sustainable profitability. **We expect the retail health GWP to maintain a high-teen FY26-28 CAGR with continued improvement in quality of business.**

Exhibit 4: STARHEAL dominates retail health insurance with growth trajectory largely aligned with the industry




Source: MOFSL, GI Council

Exhibit 5: STARHEAL dominates the retail (individual + family) lives covered




Source: MOFSL, IRDAI

Exhibit 6: Retail fresh business growth trajectory improving




Source: MOFSL, Company

Exhibit 7: Renewals have improved to 99% in FY26



Source: MOFSL, Company

Exhibit 8: Retail health GWP to maintain growth momentum




Source: MOFSL, Company

Group health strategy reset from scale to profitability

- STARHEAL's approach toward group health business has evolved over the last few years from scaling up the corporate segment during IPO to exiting corporate accounts owing to prolonged pricing irrationality, high claims inflation and weak profitability.
- As a result, the group health contribution to GWP declined from 13% in FY20 to 4% in FY26, with premium witnessing a 38% YoY decline in FY26. STARHEAL's group health market share has declined from 3.6% in FY21 to ~1% in FY26.
- The current strategy is centered around maintaining only profitability-oriented group business, with focus areas including SME/MSME cohorts and banca-linked benefit products where underwriting visibility and pricing control are materially better. SME/MSME cohorts account for ~78% of the group portfolio in FY26 compared to 58% in FY25.
- The change in strategy has led to a meaningful improvement in the group health loss ratio from 90.8% in FY25 (IndAS basis) to 79.1% in FY26 (87.3% in 4QFY25 to 73.5% in 4QFY26).
- As a result, group health is expected to remain a relatively small component of the overall business at ~4-5% over the medium term. **We expect the group health GWP to clock a CAGR of 5% over FY26-28.**

Exhibit 9: Group health GWP contribution to remain in single digits



Source: MOFSL, Company


Agency strength serves as a key distribution moat

- STARHEAL's extensive penetration across the country remains difficult to replicate, especially in a product like retail health insurance, which requires high customer engagement and servicing. Along with the largest agency force of ~830,000, the insurer has also seen continuous improvement in agent productivity to INR410,000 in FY26 (INR320,000 in FY24).
- The insurer is targeting an agency base of 1m over the next two years, with ~100,000 agent additions every year. However, the focus is high on building stable, productive cohorts rather than merely maximizing gross agent additions.
- While multiple insurers are attempting to expand agency channels aggressively, the real differentiation lies in field-level engagement, activation infrastructure, productivity management and local brand presence considering the deeper engagement, advisory and servicing requirement of health insurance.
- Digital channels are also becoming strategically important, not only from a growth perspective but also from a customer-quality and operating-leverage standpoint. The fresh business coming from digital channels has more than

doubled in the last two years, with 98% being new-to-insurance customers in FY26.


- Digital customers tend to be younger, more likely to purchase long-term policies and generally carry lower servicing intensity. Hence, the insurer continues to invest in its own D2C capabilities as well as enhance digital partners with the expectation that digital contribution will increase gradually over time.
- On the bancassurance side, STARHEAL has 81 partnerships as of FY26, including multiple mid-sized private banks, regional banks and South Indian banks, which are generating healthy traction.

Exhibit 10: Expanding agency force with improving productivity




Source: MOFSL, Company

Exhibit 11: Strong growth trajectory of digital channel fresh business




Source: MOFSL, Company

Exhibit 12: Banca partnerships increasing gradually



Source: MOFSL, Company

Exhibit 13: Fresh GWP contribution has been slow




Source: MOFSL, Company

Improvement in underwriting performance as fresh business grows


- Over the last few quarters, STARHEAL has seen the sustained improvement in underwriting performance as reflected in 200-400bp YoY improvement in the IndAS loss ratio for the last three quarters. This gives confidence around structural normalization in underwriting margins.
- The improvement has been driven by (1) strong acceleration in fresh business growth, (2) repricing actions, and (3) continued investments in prevention and wellness initiatives.
- Fresh business cohorts are younger, carry higher sum insured, exhibit better claims behavior and are contributing positively to underwriting quality. The retail IndAS claims ratio witnessed a significant improvement from 67.8% in 4QFY25 to 64.8% in 4QFY26 (68.2% in FY26 vs. 69.2% in FY25).
- The insurer had initially repriced ~55% of the portfolio during FY25, while the latest repricing cycle undertaken during Feb-May'26 will be covering ~80% of the book. However, the full flow-through benefits of these pricing actions would likely take ~18 months to reflect fully in underwriting metrics, implying that the current improvement trajectory may still have further runway.
- STARHEAL has significantly expanded its investments in prevention and wellness initiatives, with telemedicine, home healthcare and condition management programs scaling up notably during FY26 (~9x jump in customer engagement in 4QFY26). These capabilities enhance customer servicing and help in reducing claims frequency and improving severity management over time. Hospital management and negotiation capabilities are also supporting better claims outcomes.
- Collectively, these initiatives are expected to structurally keep retail loss ratios in check and hence, we expect the overall IndAS loss ratios to remain stable at 68% for STARHEAL.
- Opex ratio (IndAS basis) has been maintained near 30% (30.2% in FY26). Improving agent productivity, rising contribution from renewals and increasing digital penetration should drive operating leverage. We expect the ratio to be stable at ~30%.
- The combination of a stable loss ratio and maintained operational leverage will keep the combined insurance service ratio (CISR) at ~98% in the medium term. A normalized investment yield of ~8% and 2x leverage can support sustainable mid-teen RoE over the medium term.

Exhibit 14: Loss ratios improve across segments



Source: MOFSL, Company. Note: Based on IndAS financials

Exhibit 15: CISR expected to remain stable



Source: MOFSL, Company. Note: Based in IndAS financials

Transitioning to a new accounting framework - IFRS

- The Indian insurance sector is entering a meaningful transition phase with the adoption of IFRS-based accounting standards and evolving risk-based solvency frameworks.
- IFRS reporting could introduce significantly higher volatility in reported earnings due to mark-to-market treatment of investment portfolios as witnessed in FY26 when STARHEAL's investment yield declined to 5.8% from 7.6% in FY25. However, a normalized investment yield of 8% paints a realistic picture with respect to RoE.
- STARHEAL's investment portfolio remains predominantly fixed-income oriented, with more than ~80% of assets invested in debt securities. Equity exposure remains relatively moderate compared to life insurers, which should partially mitigate earnings volatility under IFRS.
- The risk-based solvency framework should ideally allocate retail health as lower-risk intensity business, given the short-tail nature, but the final framework remains under consultation.
- With the potential commission regulations, the regulator's focus is on institutional distributors, bancassurance partnerships and channels where distributor payouts have increased materially after the shift toward EoM-based frameworks.
- Agency-led models are relatively less exposed to potential regulatory tightening, especially given that agency commissions have already normalized meaningfully over time, partly aided by GST-related adjustments. Given STARHEAL's dominant proprietary agency distribution and relatively lower dependence on institutional distribution compared to some peers, the company could potentially emerge relatively better positioned under tighter commission frameworks.

Exhibit 16: IFRS P&L


INRm	FY24	FY25	FY26	FY27E	FY28E
Insurance Revenue	1,36,630	1,59,430	1,79,986	2,08,783	2,42,189
% YoY growth		16.7	12.9	16.0	16.0
Insurance Service Expense	90,870	1,11,340	1,22,740	1,41,973	1,64,688
Deferred acquisition cost	32,160	37,370	42,400	49,690	57,641
Net expenses from reinsurance	1,080	1,590	1,538	1,784	2,070
Insurance service result	12,520	9,130	13,308	15,336	17,790
Investment income	11,730	12,620	10,908	16,695	18,725
Other income					
Other operating expenses	9,260	10,800	10,925	12,451	14,113
Finance costs	190	410	947.6	1,137	1,365
PBT	14,800	10,540	12,343	18,444	21,037
Tax	3,760	2,670	3,229	4,611	5,259
PAT	11,040	7,870	9,114	13,833	15,778
EPS	18.9	13.4	15.5	23.5	26.8
Assuming normalized investment yield of 8%					
PAT	10,340	8,400	12,200		

Source: MOFSL, Company

Valuation and View

- STARHEAL increasingly appears to be transitioning toward a structurally improving retail health franchise built around stronger cohort quality, better underwriting discipline and deep distribution capabilities.
- The combination of strong fresh business growth, younger customer acquisition, calibrated repricing, higher long-term policy mix and investments in prevention ecosystems is beginning to materially improve underwriting outcomes.
- The company's dominant agency distribution platform, particularly across non-tier-1 geographies, continues to provide a significant competitive advantage in a category where customer engagement and servicing remain critical.
- Key monitorables would be (1) retail loss ratio improvement, (2) fresh business growth, (3) group health profitability, (4) impact of potential commission regulations, and (5) operational leverage to keep CISR in 97-98% range and RoE in mid-teens.
- We estimate a CAGR of 16%/32% in IFRS insurance revenue/PAT during FY26-28, with the CISR improving to 98.3% in FY28E. We maintain BUY rating on the stock with a TP of INR700 (valuing the company at 26x FY28E IFRS PAT).

Exhibit 17: One-year forward P/E chart



Source: MOFSL, Company

Financials and valuations

Income Statement								(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
Retail Health	58,252	82,075	1,00,870	1,19,475	1,39,512	1,54,130	1,77,430	2,09,367	2,40,773
Group Health	8,897	9,963	12,066	8,076	10,824	11,038	6,839	6,839	7,523
PA	1,337	1,489	1,685	1,939	2,117	1,897	1,704	2,045	2,352
Total GDPI	68,651	93,885	1,14,635	1,29,525	1,52,545	1,67,814	1,86,219	2,18,251	2,50,647
Change (%)	27.1	36.8	22.1	13.0	17.8	10.0	11.0	17.2	14.8
NWP	52,395	71,794	1,08,096	1,23,197	1,40,674	1,55,252	1,76,503	2,06,863	2,37,569
NEP	46,841	46,266	98,092	1,12,616	1,29,383	1,48,222	1,65,967	1,93,417	2,22,127
Change (%)	27.9	-1.2	112.0	14.8	14.9	14.6	12.0	16.5	14.8
Net claims	30,874	43,695	85,400	73,204	85,940	1,04,194	1,13,752	1,31,524	1,51,046
Net commission	3,404	5,857	14,922	16,828	18,596	22,407	26,733	31,029	35,635
Expenses	11,013	14,031	18,443	20,538	23,944	25,406	29,598	33,779	37,460
Employee expenses	8,526	11,765	13,436	14,537	16,122	16,929	19,832	22,608	24,869
Other expenses	2,487	2,266	5,007	6,001	7,823	8,477	9,767	11,171	12,591
Underwriting Profit/(Loss)	1,550	-17,316	-20,673	2,046	903	-3,785	-4,116	-2,915	-2,015
Investment income (PH)	1,639	2,505	4,796	5,014	6,407	7,718	7,742	10,254	11,982
Operating profit	3,303	-14,811	-15,877	7,061	7,309	3,933	3,626	7,339	9,967
Investment income (SH)	1,212	1,718	3,214	3,287	4,089	5,135	4,610	5,601	6,759
PBT	4,062	-14,458	-14,024	8,264	11,289	8,611	7,543	12,118	15,781
Tax	1,389	-3,601	-3,559	2,078	2,838	2,152	1,973	3,030	3,945
Tax rate (%)	34.2	24.9	25.4	25.1	25.1	25.0	26.2	25.0	25.0
PAT	2,633	-10,857	-10,464	6,186	8,450	6,459	5,570	9,089	11,836

Balance sheet								(INR m)	
Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
Equity Share Capital	4,906	5,481	5,755	5,817	5,853	5,878	5,884	5,884	5,884
Reserves & Surplus	14,132	29,516	40,285	59,839	60,429	64,359	70,008	79,097	90,933
Net Worth	19,038	34,996	46,040	65,656	66,282	70,236	75,892	84,981	96,817
FV change	31	-76	267	234	1,036	885	-380	885	974
Borrowings	2,500	2,500	7,200	4,700	4,700	4,700	4,700	4,700	4,700
Other liabilities	38,361	67,589	81,629	92,988	1,08,525	1,32,025	1,60,426	1,80,456	2,05,616
Total Liabilities	59,930	1,05,010	1,35,136	1,63,577	1,80,543	2,07,846	2,40,638	2,71,021	3,08,107
Investments (SH)	18,110	27,941	44,939	53,459	63,361	71,857	75,108	84,859	96,561
Investments (PH)	24,789	40,426	68,796	80,462	91,548	1,07,126	1,25,016	1,46,483	1,71,170
Net Fixed Assets	1,019	990	1,171	1,113	1,751	1,849	1,803	1,853	1,903
Def Tax Assets	70	4,213	7,767	5,689	3,582	3,512	3,561	3,561	3,561
Current Assets	9,827	12,650	6,828	8,444	12,990	16,817	20,715	24,279	27,882
Cash & Bank	6,114	18,790	5,635	14,410	7,312	6,684	14,436	9,988	7,030
Total Assets	59,930	1,05,010	1,35,136	1,63,577	1,80,543	2,07,846	2,40,638	2,71,021	3,08,107

Financials and valuations

Ratios

Y/E March	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
GWP growth	27.1	36.8	22.1	13.0	17.8	10.0	11.0	17.2	14.8
NWP growth	26.9	37.0	50.6	14.0	14.2	10.4	13.7	17.2	14.8
NEP growth	27.9	-1.2	112.0	14.8	14.9	14.6	12.0	16.5	14.8
Claim ratio	65.9	94.4	87.1	65.0	66.4	70.3	68.5	68.0	68.0
Commission ratio	6.5	8.2	13.8	13.7	13.2	14.4	15.1	15.0	15.0
Expense ratio	21.0	19.5	17.1	16.7	17.0	16.4	16.8	16.3	15.8
Combined ratio	93.4	122.1	117.9	95.3	96.7	101.1	100.5	99.3	98.8

Profitability Ratios (%)

RoE	16.8	-40.2	-25.8	11.1	12.8	9.5	7.6	11.3	13.0
-----	------	-------	-------	------	------	-----	-----	------	------

Valuations	2020	2021	2022	2023	2024	2025	2026	2027E	2028E
BVPS (INR)	38.8	63.9	80.0	112.9	113.2	119.5	129.0	144.4	164.5
Change (%)	43.9	64.6	25.3	41.1	0.3	5.5	7.9	12.0	13.9
Price-BV (x)	14.9	9.0	7.2	5.1	5.1	4.8	4.5	4.0	3.5
EPS (INR)	5.4	-19.8	-18.2	10.6	14.4	11.0	9.5	15.4	20.1
Change (%)	15.8	-469.1	-8.2	-158.5	35.8	-23.9	-13.9	63.2	30.2
Price-Earnings (x)	107.5	-29.1	-31.7	54.3	40.0	52.5	61.0	37.4	28.7
Market Cap/GDPI (x)	4.9	3.6	3.0	2.6	2.2	2.0	1.8	1.6	1.4

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.